Literature DB >> 24146028

Bone: Strontium ranelate does not have an anabolic effect on bone.

Glen M Blake1, Ignac Fogelman.   

Abstract

Strontium ranelate, a therapeutic for osteoporosis, was thought to have a dual mode of action, simultaneously stimulating bone formation and reducing resorption. A recent study casts doubt on this explanation, suggesting instead that it has a mild suppressive effect on bone formation with little effect on bone resorption.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24146028     DOI： 10.1038/nrendo.2013.210

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  10 in total

1.  Could strontium ranelate have a synergistic role in the treatment of osteoporosis?

Authors:  Glen M Blake; Juliet E Compston; Ignac Fogelman
Journal:  J Bone Miner Res       Date:  2009-08       Impact factor: 6.741

2.  Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

Authors:  J Y Reginster; E Seeman; M C De Vernejoul; S Adami; J Compston; C Phenekos; J P Devogelaer; M Diaz Curiel; A Sawicki; S Goemaere; O H Sorensen; D Felsenberg; P J Meunier
Journal:  J Clin Endocrinol Metab       Date:  2005-02-22       Impact factor: 5.958

Review 3.  How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis.

Authors:  P J Marie; D Felsenberg; M L Brandi
Journal:  Osteoporos Int       Date:  2010-09-02       Impact factor: 4.507

4.  Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate.

Authors:  Pascale Chavassieux; Pierre J Meunier; Jean Paul Roux; Nathalie Portero-Muzy; Marlène Pierre; Roland Chapurlat
Journal:  J Bone Miner Res       Date:  2014-03       Impact factor: 6.741

5.  In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization.

Authors:  G Boivin; D Farlay; M T Khebbab; X Jaurand; P D Delmas; P J Meunier
Journal:  Osteoporos Int       Date:  2009-07-14       Impact factor: 4.507

6.  Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate.

Authors:  Monique E Arlot; Yebin Jiang; Harry K Genant; Jenny Zhao; Brigitte Burt-Pichat; Jean-Paul Roux; Pierre D Delmas; Pierre J Meunier
Journal:  J Bone Miner Res       Date:  2008-02       Impact factor: 6.741

7.  The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.

Authors:  Pierre J Meunier; Christian Roux; Ego Seeman; Sergio Ortolani; Janusz E Badurski; Tim D Spector; Jorge Cannata; Adam Balogh; Ernst-Martin Lemmel; Stig Pors-Nielsen; René Rizzoli; Harry K Genant; Jean-Yves Reginster
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245

8.  Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

Authors:  Robert R Recker; Fernando Marin; Sophia Ish-Shalom; Rüdiger Möricke; Federico Hawkins; Georgios Kapetanos; María P de la Peña; Jörn Kekow; Jordi Farrerons; Beatriz Sanz; Heide Oertel; Jan Stepan
Journal:  J Bone Miner Res       Date:  2009-08       Impact factor: 6.741

9.  Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength.

Authors:  Patrick Ammann; Isabelle Badoud; Sébastien Barraud; Romain Dayer; René Rizzoli
Journal:  J Bone Miner Res       Date:  2007-09       Impact factor: 6.741

10.  Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry.

Authors:  S P Nielsen; D Slosman; O H Sørensen; B Basse-Cathalinat; P De Cassin; C R Roux; P J Meunier
Journal:  J Clin Densitom       Date:  1999       Impact factor: 2.963
  10 in total
  1 in total

Review 1.  Treatment of primary osteoporosis in men.

Authors:  Andrea Giusti; Gerolamo Bianchi
Journal:  Clin Interv Aging       Date:  2014-12-30       Impact factor: 4.458
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.